AROGUARD ODOR NEUTRALIZER SYSTEM

المعلومات الرئيسية

  • اسم تجاري:
  • AROGUARD ODOR NEUTRALIZER SYSTEM
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • AROGUARD ODOR NEUTRALIZER SYSTEM
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 917210
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

1 / 7

AROGUARD ODOR NEUTRALIZER SYSTEM

Kay Chemical Company

8300 Capital Drive

Greensboro, North Carolina USA 27409

1-800-529-5458

1-877-231-2615 (USA/Canada), 952-853-1713 (outside USA)

24.05.2017

GHS

:

:

:

(%)

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

2 / 7

Linalool

78-70-6

1 - 5

Benzyl salicylate

118-58-1

1 - 5

Hydroxy-citronellal

107-75-5

1 - 5

Citronellol

106-22-9

1 - 5

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

3 / 7

0 °C

50 °C

1.003

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

4 / 7

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

5 / 7

> 5,000 mg/kg :

> 5,000 mg/kg :

Linalool

96 h :

LC50

27.8 mg/l :

Benzyl salicylate

96 h :

LC50

1.03 mg/l :

Hydroxy-citronellal

48 h :

EC50

68 mg/l :

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

6 / 7

(ADR/ADN/RID)

)

IMDG/

(

24.05.2017

Regulatory Affairs

AROGUARD ODOR NEUTRALIZER SYSTEM

917210

7 / 7

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

6-7-2018

Expanded Recall: Peg Perego Canada Inc. recalls Various Book Strollers

Expanded Recall: Peg Perego Canada Inc. recalls Various Book Strollers

Health Canada's sampling and evaluation program has determined that these strollers do not meet the Carriages and Strollers Regulations in Canada. Specifically, the strollers do not meet the latching system requirements for folding strollers as they do not have a safety device independent of the latching device to prevent folding.

Health Canada

3-7-2018

Public Notification: Body Shape Weight Loss System contains hidden drug ingredient

Public Notification: Body Shape Weight Loss System contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Body Shape Weight Loss System, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

29-6-2018

Talking Rain® Voluntarily Recalls Sparkling Ice® Cherry Limeade in Response to Customer Complaints

Talking Rain® Voluntarily Recalls Sparkling Ice® Cherry Limeade in Response to Customer Complaints

Talking Rain® (the Company) is voluntarily recalling specific lot codes of bottles of its Sparkling Ice® Cherry Limeade beverage in response to a small number of customer complaints that reported an off-taste and off-odor of the affected product. The Company made the decision to recall the product out of an abundance of caution.

FDA - U.S. Food and Drug Administration

21-6-2018

FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients

FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients

FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients

FDA - U.S. Food and Drug Administration

21-6-2018

FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes

FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes

glucose monitoring system, implantable glucose sensor, adults, diabetes

FDA - U.S. Food and Drug Administration

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

1-6-2018

FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files

FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files

FDA Adverse Event Reporting System (FAERS) - Quarterly Data Extract (QDE): The Quarterly Data Extract files, contain raw data extracted from the FAERS database for the indicated time ranges (not cumulative), in ASCII or SGML formats.

FDA - U.S. Food and Drug Administration

1-6-2018

FDA Adverse Event Reporting System (FAERS) Public Dashboard

FDA Adverse Event Reporting System (FAERS) Public Dashboard

Four FAERS summary statistics reports updated with data through December 31, 2013.

FDA - U.S. Food and Drug Administration

1-6-2018

HeartWare HVAD System by Medtronic: Class I Recall - Due to Unintended Intermittent Electrical Disconnection between the Power Source and the Controller

HeartWare HVAD System by Medtronic: Class I Recall - Due to Unintended Intermittent Electrical Disconnection between the Power Source and the Controller

Interruptions to the electrical connection could cause a pump stop. A pump stop could cause patient harm such as exacerbation of heart failure symptoms, or symptoms such as mild weakness, loss of consciousness, or death.

FDA - U.S. Food and Drug Administration

30-5-2018

Climate change and health

Climate change and health

Climate change is a reality on which there is broad consensus in the scientific community. Because of the inertia of the climate system, changes to the climate related to human activities will continue for many years, regardless of any measures taken today. Combating climate change, which is part of a more global environmental change, is therefore essential to limit its magnitude.

France - Agence Nationale du Médicament Vétérinaire

25-5-2018

Nosocomial infections can also be caused by the Bacillus cereus bacterium

Nosocomial infections can also be caused by the Bacillus cereus bacterium

While Bacillus cereus is well known as a source of food infections, researchers from INRA and ANSES, working with doctors at nine French hospitals[1] including those in the Paris Public Hospital System (AP-HP), have demonstrated for the first time that this bacterium is also responsible for inter- and intra-hospital nosocomial contamination.

France - Agence Nationale du Médicament Vétérinaire

24-5-2018

Three questions for Gilles Salvat, ANSES Managing Director General for Research and Reference

Three questions for Gilles Salvat, ANSES Managing Director General for Research and Reference

As Reference Delegation Day is held at ANSES, bringing together representatives of national and European reference laboratories, Gilles Salvat, Managing Director General for Research and Reference, gives us an overview of this essential part of ANSES's work. What do you mean by reference? Reference is an essential component of the system for safeguarding health. The work of the reference laboratories is vital to improving knowledge and identification of the major hazards we face in food safety, animal...

France - Agence Nationale du Médicament Vétérinaire

22-5-2018

HeartMate 3™ Left Ventricular Assist System: Class I Recall - Due to Potential Malfunction that may Lead to Graft Occlusion

HeartMate 3™ Left Ventricular Assist System: Class I Recall - Due to Potential Malfunction that may Lead to Graft Occlusion

The class I recall is due to a malfunction in the device’s outflow graft assembly that may cause the outflow graft to twist and close up (occlusion) over time. Occlusion of the outflow graft can reduce or stop pump flow and set off a persistent low flow alarm in the system. A reduction in pump can lead to serious adverse events such as blood clots and death.

FDA - U.S. Food and Drug Administration

15-5-2018

Fireplace Products International Ltd. (FPI) recalls Regency Ultimate U37 and U39 Direct Vent Gas Stove Fireplaces

Fireplace Products International Ltd. (FPI) recalls Regency Ultimate U37 and U39 Direct Vent Gas Stove Fireplaces

The pressure release system can fail and cause the gas stove to explode, posing a laceration hazard.

Health Canada

3-5-2018

FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)

FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system.

FDA - U.S. Food and Drug Administration

25-4-2018

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...

FDA - U.S. Food and Drug Administration

27-2-2018

Therakos Cellex Photopheresis System

Therakos Cellex Photopheresis System

Update: Therakos Cellex Photopheresis System Safety advisory – risk of blood clots

Therapeutic Goods Administration - Australia

12-9-2017

E2B acknowledgment format change

E2B acknowledgment format change

Companies that use the Danish Medicines Agency's Pharmacovigilance System should be aware that we have changed the MessageFormatRelease value from 2.0 to 1.0.

Danish Medicines Agency

13-1-2016

Access to results in EudraCT from 13 January

Access to results in EudraCT from 13 January

When a clinical trial of medicinal products has ended, the trial results must be entered in the EudraCT database. The system has been unavailable for a period of time during which data could not be entered in the EudraCT database. The EMA now re-opens the database and results can be entered in EudraCT again.

Danish Medicines Agency

12-6-2015

CUG certificates for login to DKMAnet must be replaced

CUG certificates for login to DKMAnet must be replaced

The Danish Health and Medicines Authority has to replace the system used to issue Closed User Group (CUG) certificates to users of DKMAnet who cannot obtain a NemID employee certificate, i.e. primarily users employed in companies without a Danish CVR registration number. If you are currently using a CUG certificate of the old type to log in to DKMAnet, you must obtain a new certificate before 1 September 2015.

Danish Medicines Agency

15-8-2011

Reassessment of reimbursement status of strong analgesics (opioids)

Reassessment of reimbursement status of strong analgesics (opioids)

On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N (nervous system) starting with the ATC subgroup N06A (antidepressants) and then N02A (opioids). The Reimbursement Committee is having the initial discussions of the opioids at its meeting on 23 August 2011.

Danish Medicines Agency

7-1-2010

The Danish Medicines Agency initiates the reassessment of reimbursement status of medicines in ATC group N

The Danish Medicines Agency initiates the reassessment of reimbursement status of medicines in ATC group N

The Danish Medicines Agency initiates its reassessment of the reimbursement status of medicines in ATC group N (Nervous system). It will take place concurrently with the reassessment process for the remaining subgroups in ATC groups A and J.

Danish Medicines Agency

24-4-2006

Reassessment of subgroups in ATC group C

Reassessment of subgroups in ATC group C

The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.

Danish Medicines Agency

12-7-2018

TGA presentations: The new Code - where are we at? 12 & 13 June 2018

TGA presentations: The new Code - where are we at? 12 & 13 June 2018

These presentations provided an update on the implementation of the new Therapeutic Goods Advertising Code and complaints system

Therapeutic Goods Administration - Australia

22-6-2018

FDA expands approval of hybrid closed loop system for monitoring and delivering insulin to pediatric patients as young as 7. #cgm #diabetes #pediatrics #fdaapproval #medicaldevice  http://go.usa.gov/xUqgQ pic.twitter.com/wZdrU6tTzf

FDA expands approval of hybrid closed loop system for monitoring and delivering insulin to pediatric patients as young as 7. #cgm #diabetes #pediatrics #fdaapproval #medicaldevice http://go.usa.gov/xUqgQ pic.twitter.com/wZdrU6tTzf

FDA expands approval of hybrid closed loop system for monitoring and delivering insulin to pediatric patients as young as 7. #cgm #diabetes #pediatrics #fdaapproval #medicaldevice http://go.usa.gov/xUqgQ  pic.twitter.com/wZdrU6tTzf

FDA - U.S. Food and Drug Administration

22-6-2018

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today.  #cgm #diabetes #fda #medicaldevice  https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5  pic.twitter.com/6zs99z2Dlz

FDA - U.S. Food and Drug Administration

4-6-2018

Automation of validation of eCTD and NeeS sequences

Automation of validation of eCTD and NeeS sequences

The TGA is currently undertaking work to streamline and automate our electronic dossier receipt system

Therapeutic Goods Administration - Australia

25-5-2018

The new Code - where are we at?

The new Code - where are we at?

Webinar and information session on the implementation of the Therapeutic Goods Advertising Code and complaints system

Therapeutic Goods Administration - Australia

14-5-2018

Regulatory and procedural guideline:  EudraVigilance user manual for marketing authorisation holders

Regulatory and procedural guideline: EudraVigilance user manual for marketing authorisation holders

Marketing Authorisation Holders - EudraVigilance access via the EudraVigilance Data Analysis System

Europe - EMA - European Medicines Agency